Dianthus Therapeutics, Inc.

The current price of DNTH is $86.03 — it has increased by 3.64% since the previous close. Data as of Nov 6, 2026.

DNTH is up 4.33% over the past week, up 1.35% over the past month and up 137.13% over the past year. The price is above its 200-day moving average of $85.95.

Analysts' average 12-month price target for DNTH is $133.20, which implies 54.83% upside from the current price. Individual estimates range from $120.00 to $158.00.

Dianthus Therapeutics, Inc. has a market capitalization of $4.81B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Dianthus Therapeutics, Inc. posted a loss of $0.81 per share against an estimate of -$0.9445, beating expectations by 14.24%. Upcoming reports are listed in the earnings calendar.

Dianthus Therapeutics, Inc. reported revenue of $1.21M in its most recent quarter, which has increased by 205.56% compared with the same quarter a year earlier. Analysts had expected $460.93K.

Companies most comparable to Dianthus Therapeutics, Inc. include Immunovant, Inc., Vera Therapeutics, Inc., AnaptysBio, Inc., MoonLake Immunotherapeutics and Alumis Inc.

In the latest trading session DNTH moved between $82.13 and $87.44, a range of 6.18% of its current price.

Over the past 52 weeks DNTH has traded between $34.29 and $117.88. The current price is 27.02% below its 52-week high.